NICE rejects Sanofi's Jevtana, citing cancer drug's side effects PMLiVE NICE's final draft guidance does not recommend Jevtana (cabazitaxel) in combination with prednisone or prednisolone in prostate cancer that had progressed despite treatment with docetaxel because of the side effect burden with the drug, according to ... |
